Latest news
Otsuka’s Voyxact raises the bar in IgA nephropathy - biocentury.combiocentury.com · Fri, 07 Aug 2026 22:14:00 GMTIgA nephropathy in a patient with 17α-hydroxylase/17,20-lyase deficiency caused by the CYP17A1 p. Y329fs mutation: a case report and review - springermedicine.comspringermedicine.com · Fri, 07 Aug 2026 06:00:11 GMTAlternative complement pathway overactivation in IgA nephropathy - Vera HealthVera Health · Wed, 05 Aug 2026 19:42:40 GMTHow Has IgAN Affected Your Marriage? - HealthCentralHealthCentral · Wed, 05 Aug 2026 18:51:54 GMTAtacicept Shows Encouraging Safety Profile in IgA Nephropathy: Richard Lafayette, MD - The American Journal of Managed Care® (AJMC®)The American Journal of Managed Care® (AJMC®) · Wed, 05 Aug 2026 16:41:27 GMTOtsuka's VOYXACT hits VISIONARY two-year eGFR goal in IgA nephropathy - app.dealroom.coapp.dealroom.co · Wed, 05 Aug 2026 04:43:21 GMTSibeprenlimab (Voyxact) Stabilizes Kidney Function in IgAN - HCPLiveHCPLive · Tue, 04 Aug 2026 15:04:13 GMTOtsuka reports VOYXACT phase 3 eGFR gain in IgA nephropathy - International Business TimesInternational Business Times · Tue, 04 Aug 2026 14:43:23 GMT